Former Wyeth chief executive joins private equity firm

Company: Piramal Pharma Solutions

He will advise The Carlyle Group’s global healthcare division

Robert Essner, former chief executive of Wyeth, has joined private equity firm The Carlyle Group as senior advisor to its global healthcare division.

Essner will provide strategic guidance to Carlyle professionals throughout the healthcare investment process, from sourcing to purchase, and advise portfolio company executives on management, operational and growth strategies.

Essner worked at Wyeth from 1989–2008, where he led Wyeth’s transformation into a global leader in biotechnology and vaccines. He was elected chief executive and in 2003 he became chairman; he retired from both positions in 2008.

The Carlyle Group is a global private equity firm with US$88.6bn of assets under management committed to 67 funds as of 31 December, 2009.

You may also like

Finance

Piramal Pharma Limited announces results for Q3 and 9M FY26

Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31st December 2025
Manufacturing

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth
Finance

Piramal and NewAmsterdam Pharma invest in a dedicated suite to enhance oral solid dosage production

The multimillion-dollar investment provides NewAmsterdam Pharma with the commercial capacity to produce a fixed-dose combination (FDC) of obicetrapib and ezetimibe to meet commercial demand
Manufacturing

Piramal Pharma posts steady Q1FY26 results with growth in CDMO and consumer segments

Company maintains zero OAI status, expands US capacity, and sees strong e-commerce gains
Finance

Piramal Pharma Limited announces results for Q3 and 9M FY25

Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Months (9M) ended 31st December 2024
Manufacturing

Piramal Pharma Limited reports robust growth in CDMO and sustainability initiatives

US$80 million Lexington expansion to double sterile fill-finish capacity
Finance

Piramal Pharma releases Q2 results for FY2025

The company's CDMO business is driving its growth significantly, with a 17% increase YoY
Subscribe now